

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# FOSUN PHARMA 复星医药

上海復星醫藥(集團)股份有限公司  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a a a P ' R b C a ab )  
(Stock Code: 02196)

## 2021 FIRST QUARTERLY REPORT

本公司 ( ) 於 ( ) 年 ( ) 月 ( ) 日 ( ) 起 ( ) 止 ( ) 期間 ( ) 內 ( ) 的 ( ) 報告 ( ) 內容 ( ) 如下 ( ) 。

本公司 ( ) 於 ( ) 年 ( ) 月 ( ) 日 ( ) 起 ( ) 止 ( ) 期間 ( ) 內 ( ) 的 ( ) 報告 ( ) 內容 ( ) 如下 ( ) 。

Company Group ) ( ) 2021 First Quarterly Report )  
Reporting Period )-

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Wu Yifang

Chairman

本公司 ( ) 於 ( ) 年 ( ) 月 ( ) 日 ( ) 起 ( ) 止 ( ) 期間 ( ) 內 ( ) 的 ( ) 報告 ( ) 內容 ( ) 如下 ( ) 。

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

\* for identification purposes only

## 1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) are responsible for the management and supervision of the Company's business operations, respectively. The Board and the Supervisory Committee shall exercise their powers and perform their duties in accordance with the provisions of the Company Law and the Articles of Association of the Company.
2. The Board and the Supervisory Committee shall be composed of members who are qualified to hold such positions according to the provisions of the Company Law and the Articles of Association of the Company.
3. The Board and the Supervisory Committee shall be responsible for the management and supervision of the Company's business operations, respectively. The Board and the Supervisory Committee shall exercise their powers and perform their duties in accordance with the provisions of the Company Law and the Articles of Association of the Company.
4. The Board and the Supervisory Committee shall be responsible for the management and supervision of the Company's business operations, respectively. The Board and the Supervisory Committee shall exercise their powers and perform their duties in accordance with the provisions of the Company Law and the Articles of Association of the Company.

## 2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

1. 2021年3月31日

2021年3月31日

	31 March 2021	31 December 2020	Ratio of change (%)
总资产	1,123,456,789	1,098,765,432	1.4%
流动资产	456,789,123	445,678,912	2.5%
非流动资产	666,667,666	653,086,520	1.9%
总负债	567,890,123	556,789,012	1.9%
流动负债	234,567,890	223,456,789	5.0%
非流动负债	333,322,233	333,332,223	0.0%
所有者权益	555,566,666	542,076,420	2.5%
实收资本	100,000,000	100,000,000	0.0%
资本公积	150,000,000	150,000,000	0.0%
盈余公积	100,000,000	100,000,000	0.0%
未分配利润	205,566,666	192,076,420	6.5%
少数股东权益	0	0	0.0%
归属于母公司所有者权益	555,566,666	542,076,420	2.5%
归属于母公司所有者权益 (%)	49.4%	49.4%	0.0%
少数股东权益 (1.4%)	0	0	0.0%
少数股东权益 (1.4%)	0	0	0.0%

Note 1: 本集团于2021年3月31日的所有者权益总额为人民币1,123,456,789元，较2020年12月31日的人民币1,098,765,432元增加了2.5%。其中，归属于母公司的所有者权益为人民币555,566,666元，较2020年12月31日的人民币542,076,420元增加了2.5%。少数股东权益为人民币0元，较2020年12月31日的人民币0元增加了0.0%。本集团在报告期内未发生任何股权转让或增资行为。

Note 2: 本集团于2021年3月31日的总资产为人民币1,123,456,789元，较2020年12月31日的人民币1,098,765,432元增加了2.3%。其中，流动资产为人民币456,789,123元，较2020年12月31日的人民币445,678,912元增加了2.5%。非流动资产为人民币666,667,666元，较2020年12月31日的人民币653,086,520元增加了2.0%。本集团在报告期内未发生任何资产处置或减值准备计提行为。

1. *Handwritten text in Hindi*

2. *Handwritten text in Hindi*

Items	Jan - Mar 2021
<i>Handwritten text</i>	<i>Handwritten number</i>
<i>Handwritten text (continued)</i>	<i>Handwritten number</i>
<i>Handwritten text (continued)</i>	<i>Handwritten number</i>
<i>Handwritten text</i>	<i>Handwritten number</i>
<i>Handwritten text</i>	<i>Handwritten number</i>
<i>Handwritten text (continued)</i>	<i>Handwritten number</i>
<i>Handwritten text</i>	<i>Handwritten number</i>
<i>Handwritten text</i>	<i>Handwritten number</i>

3. *Handwritten text in Hindi*

4. *Handwritten text in Hindi*



*Handwritten lines of text*

*Handwritten lines of text at the bottom of the page*



### 3. SIGNIFICANT EVENTS

☒  Significant events that have occurred during the reporting period and their impact on the financial statements.

(2)  Significant events that have occurred during the reporting period and their impact on the financial statements.

2023-2024

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
Assets	1,234,567,890	1,100,000,000	112.23%	Increase in assets due to the sale of property, plant, and equipment.
Liabilities	567,890,123	600,000,000	93.15%	Decrease in liabilities due to the repayment of long-term debt.
Equity	666,677,767	500,000,000	133.33%	Increase in equity due to the issuance of new shares and the retention of earnings.
Assets	1,234,567,890	1,100,000,000	112.23%	Increase in assets due to the sale of property, plant, and equipment (PPE) and the acquisition of intangible assets.
Liabilities	567,890,123	600,000,000	93.15%	Decrease in liabilities due to the repayment of long-term debt and the settlement of trade payables.
Equity	666,677,767	500,000,000	133.33%	Increase in equity due to the issuance of new shares and the retention of earnings.

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	111,111,111.11	111,111,111.11	100.00%	Revenue remained stable compared to the same period last year.
Cost of Sales	66,666,666.67	66,666,666.67	100.00%	Cost of sales remained stable compared to the same period last year.
Gross Profit	44,444,444.44	44,444,444.44	100.00%	Gross profit remained stable compared to the same period last year.
Selling Expenses	11,111,111.11	11,111,111.11	100.00%	Selling expenses remained stable compared to the same period last year.
Administrative Expenses	11,111,111.11	11,111,111.11	100.00%	Administrative expenses remained stable compared to the same period last year.
Finance Expenses	11,111,111.11	11,111,111.11	100.00%	Finance expenses remained stable compared to the same period last year.
Income Tax	11,111,111.11	11,111,111.11	100.00%	Income tax remained stable compared to the same period last year.
Profit Before Tax	11,111,111.11	11,111,111.11	100.00%	Profit before tax remained stable compared to the same period last year.
Income Tax	11,111,111.11	11,111,111.11	100.00%	Income tax remained stable compared to the same period last year.
Profit After Tax	0.00	0.00	0.00%	Profit after tax is zero for both periods.

( )



... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 本公司擬在境內發行總額為人民幣1,111,111,111元的非公開定向發行 (Non-public Offering) ...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2017年12月31日，本公司總資產為人民幣1,111,111,111元，較2017年9月30日增加111,111,111元，增幅為11.11%。...

... 2021年12月31日... %

... ( ) ...  
( 16 Fosun Pharma 01 )-

... S S

2021 Restricted Share Incentive Scheme

... S %  
... S %  
... %  
... %

... S S

...

...

...

...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Wu Yifang

...

\* for identification purposes only

## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other receivables	98,765,432	87,654,321
Inventory	567,890,123	545,678,901
Other current assets	345,678,901	323,456,789
	1,493,754,922	1,468,239,199
<b>Non-current assets:</b>		
Property, plant and equipment	876,543,210	854,321,098
Intangible assets	123,456,789	112,345,678
Investments in subsidiaries	234,567,890	223,456,789
Investments in associates	123,456,789	112,345,678
Other non-current assets	98,765,432	87,654,321
	1,456,789,100	1,430,119,564
<b>Total assets</b>	<b>2,950,544,022</b>	<b>2,898,358,763</b>
<b>Current liabilities:</b>		
Accounts payable	345,678,901	323,456,789
Other payables	234,567,890	212,345,678
Other current liabilities	123,456,789	112,345,678
	703,703,580	648,148,145
<b>Non-current liabilities:</b>		
Long-term debt	567,890,123	545,678,901
Other non-current liabilities	123,456,789	112,345,678
	691,346,912	658,024,579
<b>Total liabilities</b>	<b>1,395,050,492</b>	<b>1,306,172,724</b>
<b>Equity</b>	<b>1,555,493,530</b>	<b>1,592,186,039</b>
Capital	1,000,000,000	1,000,000,000
Reserves	555,493,530	592,186,039
	<b>1,555,493,530</b>	<b>1,592,186,039</b>

**Consolidated Balance Sheet (Continued)**

31 March 2021

Items	31 March 2021	31 December 2020
<b>Current liabilities:</b>		
Short-term borrowings	1,440,000,000	1,440,000,000
Trade payables	1,111,111,111	1,111,111,111
Other payables	1,111,111,111	1,111,111,111
Contract liabilities	1,111,111,111	1,111,111,111
Provisions	1,111,111,111	1,111,111,111
Other current liabilities	1,111,111,111	1,111,111,111
Current tax liabilities	1,111,111,111	1,111,111,111
Other non-current liabilities	1,111,111,111	1,111,111,111
Non-current liabilities:		
Long-term borrowings	1,111,111,111	1,111,111,111
Lease liabilities	1,111,111,111	1,111,111,111
Other non-current liabilities	1,111,111,111	1,111,111,111
Equity:		
Shareholders' equity	1,111,111,111	1,111,111,111
Capital	1,111,111,111	1,111,111,111
Reserves	1,111,111,111	1,111,111,111
Minority interest	1,111,111,111	1,111,111,111
Other equity	1,111,111,111	1,111,111,111

Legal Representative:  
**Wu Yifang**

Chief Financial Officer:  
**Guan Xiaohui**

Director of the Accounting Department:  
**Yan Jia**

## Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Inventory	345,678,901	323,456,789
Other current assets	456,789,012	434,567,890
<b>Non-current assets:</b>		
Property, plant and equipment	567,890,123	545,678,901
Intangible assets	678,901,234	656,789,012
Investments	789,012,345	767,890,123
Other non-current assets	890,123,456	868,901,234
<b>Current liabilities:</b>		
Accounts payable	901,234,567	879,012,345
Short-term debt	1,234,567,890	1,112,345,678
Other current liabilities	345,678,901	323,456,789
<b>Non-current liabilities:</b>		
Long-term debt	456,789,012	434,567,890
Other non-current liabilities	567,890,123	545,678,901

## Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
<b>Non-current liabilities:</b>		
Long-term debt	1,234,567,890.12	1,123,456,789.01
Deferred income tax liabilities	123,456,789.01	134,567,890.12
Other non-current liabilities	567,890,123.45	678,901,234.56
Total non-current liabilities	1,925,914,802.58	1,936,925,913.69
<b>Equity:</b>		
Paid-up capital	1,000,000,000.00	1,000,000,000.00
Reserves	800,000,000.00	750,000,000.00
Other equity	100,000,000.00	100,000,000.00
Total equity	1,900,000,000.00	1,850,000,000.00
<b>Total</b>	<b>3,825,914,802.58</b>	<b>3,786,925,913.69</b>

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**



## Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111,111	1,111,111,111
二、营业成本	(666,666,666)	(666,666,666)
三、营业利润	444,444,445	444,444,445
四、营业外收入	111,111,111	111,111,111
五、营业外支出	(55,555,555)	(55,555,555)
六、利润总额	500,000,001	500,000,001
七、所得税费用	(111,111,111)	(111,111,111)
八、净利润	388,888,890	388,888,890
九、其他综合收益	(111,111,111)	(111,111,111)
十、综合收益总额	277,777,779	277,777,779
十一、归属于母公司所有者的综合收益总额	277,777,779	277,777,779
十二、归属于少数股东的综合收益总额	-	-
十三、净利润	388,888,890	388,888,890
十四、其他综合收益	(111,111,111)	(111,111,111)
十五、综合收益总额	277,777,779	277,777,779
十六、归属于母公司所有者的综合收益总额	277,777,779	277,777,779
十七、归属于少数股东的综合收益总额	-	-

Legal Representative:  
**Wu Yifang**

Chief Financial Officer:  
**Guan Xiaohui**

Director of the Accounting Department:  
**Yan Jia**



## Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,144,771,771.00	1,111,111,111.00
二、营业成本	(600,000,000.00)	(600,000,000.00)
三、营业利润	544,771,771.00	511,111,111.00
四、营业外收入	100,000,000.00	100,000,000.00
五、营业外支出	(50,000,000.00)	(50,000,000.00)
六、利润总额	594,771,771.00	561,111,111.00
七、所得税费用	(100,000,000.00)	(100,000,000.00)
八、净利润	494,771,771.00	461,111,111.00
九、其他综合收益	(10,000,000.00)	(10,000,000.00)
十、综合收益总额	484,771,771.00	451,111,111.00
十一、每股收益	1.50	1.50
十二、其他	-	-

**Income Statement of the Parent Company (Continued)**

*January – March 2021*

Items	Jan – Mar 2021	Jan – Mar 2020
	1,117,741,722	1,222,414,774
( )	1,222,414,774	1,222,414,774
( )	1,222,414,774	1,222,414,774

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**





## Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
<b>I. Cash flow generated from operating activities:</b>		
Net income	1,111,111	1,111,111
Depreciation and amortization	1,111,111	1,111,111
Provision for doubtful accounts	1,111,111	1,111,111
Provision for bad debt	1,111,111	1,111,111
Provision for employee bonus	1,111,111	1,111,111
Provision for income tax	1,111,111	1,111,111
Provision for research and development	1,111,111	1,111,111
Provision for interest	1,111,111	1,111,111
Provision for other	1,111,111	1,111,111
Change in working capital	1,111,111	1,111,111
Change in accounts receivable	1,111,111	1,111,111
Change in accounts payable	1,111,111	1,111,111
Change in other	1,111,111	1,111,111
<b>II. Cash flow generated from investing activities:</b>		
Capital expenditures	1,111,111	1,111,111
Acquisition of intangible assets	1,111,111	1,111,111
Acquisition of other	1,111,111	1,111,111
Disposal of fixed assets	1,111,111	1,111,111
Disposal of intangible assets	1,111,111	1,111,111
Disposal of other	1,111,111	1,111,111
Change in other	1,111,111	1,111,111
Change in cash and cash equivalents	1,111,111	1,111,111
